人类的安全性,耐受性和药理动力学PPI-1011,一个合成等离子素前体的第一人
Tara Smith1, Kaeli J Knudsen1, Shawn A Ritchie1
1Med-Life Discoveries LP, Saskatoon, Saskatchewan, Canada.
Clinical and translational science
|March 14, 2025
概括
PPI-1011,一种合成等离子体前体,在I期研究中安全地增加了目标等离子体水平. 这提供了通过解决等离子素缺乏症来治疗Rhizomelic chondrodysplasia punctata (RCDP) 的潜力.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 根茎性肌肉发育不良点点 (RCDP) 是一种极为罕见的遗传性疾病.
- RCDP的特点是缺少等离子体原体,导致严重的身体和精神发育迟缓.
- 增加等离子素水平是RCDP的治疗策略.
研究的目的:
- 为了评估 PPI-1011 的安全性,耐受性和药理动力学, PPI-1011 是一种合成等离子素前体.
- 评估PPI-1011单次和多次上升剂量对健康成年人的影响.
主要方法:
- 第一阶段,随机,双盲,安慰剂控制的研究设计.
- 一次剂量 (10-100毫克/公斤) 和多次剂量 (75和100毫克/公斤/天) 的PPI-1011的管理.
- 对治疗出现的不良事件 (TEAE) 的监测和血清等离子素水平的药理学分析.
主要成果:
- PPI-1011是安全的,耐受性很好,所有TEAE都是轻微的和短暂的.
- 胃肠道事件是最常见的TEAE,可能是由于配方.
- 单剂和多剂PPI-1011显著增加了位等离子体的血清水平 (PlsEtn 16:0/22:6).
- 每天服用一次的疗法导致PlsEtn 16:0/22:6度持续增加至少14天.
结论:
- PPI-1011在健康成年人中显示出有利的安全性.
- PPI-1011有效增加血清等离子体水平,支持其作为RCDP治疗剂的潜力.
- 需要进一步的研究来确认RCDP患者的疗效.
相关概念视频
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
331
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
331
Drug Metabolism: Phase I Reactions
2.9K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
2.9K


